Evidence map›Paper›PMID 22552527›Full record

SynthesisJournal of neurology2012

Botulinum toxin as treatment for focal dystonia: a systematic review of the pharmaco-therapeutic and pharmaco-economic value.

E Zoons, M G W Dijkgraaf, J M Dijk, I N van Schaik, M A Tijssen

Open access · hybridAbstract readSystematic Review
In one paragraph

Synthesis in Journal of neurology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 7 pooled it
4.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 7 syntheses or guidelines pooled it, 62 citations in OpenAlex.

  1. Botulinum toxin type A versus anticholinergics for cervical dystonia.The Cochrane database of systematic reviews · 2021
    Pooled it
  2. Botulinum toxin type A therapy for blepharospasm.The Cochrane database of systematic reviews · 2020
    Pooled it
  3. Botulinum toxin type A therapy for cervical dystonia.The Cochrane database of systematic reviews · 2020
    Pooled it
  4. Botulinum toxin type A therapy for cervical dystonia.The Cochrane database of systematic reviews · 2017
    Pooled it
  5. Botulinum toxin type A versus botulinum toxin type B for cervical dystonia.The Cochrane database of systematic reviews · 2016
    Pooled it
  6. Botulinum toxin type B for cervical dystonia.The Cochrane database of systematic reviews · 2016
    Pooled it
  7. Pooled it
  8. Trial
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Observational
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

E ZoonsDepartment of Neurology, Academic Medical Centre, Amsterdam, The Netherlands.
M G W Dijkgraaf
J M Dijk
I N van Schaik
M A Tijssen
Academic Medical Center · NLUniversity Medical Center Groningen · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Focal dystonia is a common, invalidating neurologic condition characterized by involuntary, sustained muscle contractions causing twisting movements and abnormal postures in one body part. Currently, botulinum toxin is the treatment of first choice. We performed a systematic review towards the pharmaco-therapeutic and pharmaco-economic value of botulinum toxin as treatment for focal dystonia, which yielded the following results. Botulinum toxin is the most effective treatment for reducing dystonic symptoms measured with dystonia-specific and general questionnaires, and pain in patients with focal dystonia. Seventy-one percent of patients with cervical dystonia had a reduction in neck pain compared to 12 % in placebo groups. Adverse events occur in 58 % of patients during treatment with botulinum toxin compared to 46 % treated with placebo. Especially dry mouth, neck weakness, dysphagia, and voice changes are common. Adverse events are usually mild and self-limiting. Health-related quality of life, measured with the SF-36 is 20-50 points lower in patients with focal dystonia compared to controls and the effect of botulinum toxin on health-related quality of life is unclear. Botulinum toxin treatment is expensive because the drug itself is expensive. Yearly costs for treating a patient with focal dystonia with botulinum toxin range from EUR 347 to EUR 3,633 and the gain in QALYs with BTX treatment is small. Focal dystonia impairs the productivity and the ability to work. At start of botulinum toxin treatment only 47-50 % was working. Botulinum toxin partly improves this. Overall, we conclude that botulinum toxin is an expensive drug with good effects. From a societal perspective, the costs may well weigh up to the regained quality of life. However, the available literature concerning costs, health-related quality of life and labor participation is very limited. An extensive cost-effectiveness study should be performed incorporating all these aspects.

Indexed as

AnimalsBotulinum ToxinsCost-Benefit AnalysisDystonic DisordersEmploymentHumansQuality of LifeTreatment OutcomeBotulinum Toxins

Identifiers

PMID22552527
PMCPMC3506193
OpenAlexW2132458723

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.